Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
The British journal of psychiatry : the journal of mental science August 1, 2019 Álvaro López-díaz, Manuel Murillo-Izquierdo, Elisa Moreno-Mellado 21 citations
In European public health systems, ketamine therapy for treatment-resistant depression should only be considered after all guideline-recommended antidepressant strategies have been tried. The paper describes the ethical, regulatory, and procedural rules governing the off-label use of ketamine in such settings.